The device performs the function of the left ventricle of the heart and pumps the blood when the heart is too weak to do so on its own
Chennai: Fortis Malar Hospital, Chennai has successfully performed India’s first HeartMate II Left Ventricular Assist Device (LVAD) implant on a 58-year-old male patient suffering from chronic heart failure.
The successful surgery was performed by Dr. K. R. Balakrishnan, Director – Cardiac Sciences, and the team of senior doctors comprising Dr. K. G. Suresh Rao (Head of Cardiac Anaesthesia and Cardiac Critical Care), Dr. Nandkishore Kapadia (Senior Consultant Cardiothoracic Surgeon), Dr. Ravi Kumar and Dr. Madan Mohan (Senior Consultant Interventional Cardiologists).
The patient was diagnosed with coronary artery disease leading to a heart attack seven years ago. Over the years, despite medication the coronary artery disease continued to weaken his heart. It led to heart blocks and left ventricular dysfunction.
His heart function had gradually declined, eventually dropping to 20% efficiency. The situation led to renal failure. Heat transplant was the only viable solution for his fragile condition which also seemed difficult given patient’s rare blood group. This situation led Fortis Malar Hospital take a decision to perform the HeartMate II LVAD implant surgery on him.
LVAD devices have been used primarily as a bridge to a heart transplant till the U. S. Food and Drug Administration (FDA) approved them as a destination therapy. The device performs the function of the left ventricle of the heart and pumps the blood when the heart is too weak to do so on its own.
HeartMate II does not involve heart replacement, instead it attaches to the heart and is designed to take over the pumping function of the patient’s left ventricle, which is the main pumping chamber of the heart. It provides continuous flow of blood without a pulse.
HeartMate II is designed to restore blood flow throughout the body, enabling the patient to breathe more easily and feel less fatigued. The patient’s organs receive more blood than they did before receiving the LVAD, and this likely improves their organ function.